Skip to content Skip to sidebar Skip to footer

Newsletter

Oct 2023

Healthcare Stocks

Ozempic: Here’s why 2023’s star obesity treatment is causing headaches for CSL and several other biotech stocks

Ozempic is one of the few things giving CSL (ASX:CSL) shareholders sleepless nights right now. And you could argue this weight-loss drug is also having an impact on all biotech…

ByNick Sundich

Sep 2023

Healthcare Stocks

The 3 best ASX biotech stocks for September!

Here are a trio of companies that we think are the best ASX biotech stocks for September! What are the Best stocks to invest in right now? Check our buy/sell stock…

ByNick Sundich

Aug 2023

Undervalued Stocks

Here are the 3 Best ASX stocks in August

In this article, we look at the Best ASX stocks in August. We're half-way through reporting season and while not all of the stocks on this list have reported yet, they…

ByNick Sundich

Jun 2023

Life Sciences

Is CSL (ASX:CSL) now facing a more difficult FY24 than investors first thought?

After a decade of nothing but good news for investors in CSL (ASX:CSL), shares fell by ~25% between June and October, a decline sparked by profit downgrade and consequential fears…

ByNick Sundich

Jun 2023

Large Caps Tech Stocks

Here are 4 ASX 200 growth stocks to look at in FY24

Growth opportunities are harder to find among large caps, but this article recaps 4 ASX 200 growth stocks with tantalising prospects in the 12 months ahead! Do you need solid trading…

ByNick Sundich